The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Non-small-cell lung cancer (NSCLC) is frequently characterized by metastases to bone. Bisphosphonates have demonstrated efficacy in reducing the risk of skeletal-related events in cancer patients with bone metastases, including those with NSCLC. Zoledronic acid (ZA) is one of the most potent bisphosphonates and is approved for the first-line treatment of patients with multiple myeloma and bone metastases from solid tumors. Recent preclinical and clinical data suggest that ZA may also have direct and indirect anticancer effects. Several preclinical studies have provided insight into the potential mechanisms responsible for the anticancer activity of ZA, including inhibiting farnesyl pyrophosphate or geranylgeranyl pyrophosphate and activation of immune-mediated anticancer response by γδ T cells. In patients with NSCLC, ZA has been shown to reduce vascular endothelial growth factor levels with a direct correlation to clinical response. Clinical studies in this setting have shown that ZA may also provide a survival benefit and prolong time to progression. Ongoing studies are evaluating the efficacy of ZA for anticancer activity and prevention of bone metastases. Bisphosphonates, particularly ZA, are generally well tolerated and may likely offer an adjunct therapeutic option for patients with NSCLC.

Original languageEnglish
Pages (from-to)26-32
Number of pages7
JournalClinical Lung Cancer
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

zoledronic acid
Non-Small Cell Lung Carcinoma
Diphosphonates
Neoplasm Metastasis
Bone and Bones
Therapeutics
Multiple Myeloma
Vascular Endothelial Growth Factor A
Neoplasms

Keywords

  • Bisphosphonates
  • Bone metastases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer. / Mahtani, Reshma; Khan, Raza; Jahanzeb, Mohammad.

In: Clinical Lung Cancer, Vol. 12, No. 1, 01.01.2011, p. 26-32.

Research output: Contribution to journalArticle

@article{d02dfd25c745458d86f6a3a7dcf5f48b,
title = "The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer",
abstract = "Non-small-cell lung cancer (NSCLC) is frequently characterized by metastases to bone. Bisphosphonates have demonstrated efficacy in reducing the risk of skeletal-related events in cancer patients with bone metastases, including those with NSCLC. Zoledronic acid (ZA) is one of the most potent bisphosphonates and is approved for the first-line treatment of patients with multiple myeloma and bone metastases from solid tumors. Recent preclinical and clinical data suggest that ZA may also have direct and indirect anticancer effects. Several preclinical studies have provided insight into the potential mechanisms responsible for the anticancer activity of ZA, including inhibiting farnesyl pyrophosphate or geranylgeranyl pyrophosphate and activation of immune-mediated anticancer response by γδ T cells. In patients with NSCLC, ZA has been shown to reduce vascular endothelial growth factor levels with a direct correlation to clinical response. Clinical studies in this setting have shown that ZA may also provide a survival benefit and prolong time to progression. Ongoing studies are evaluating the efficacy of ZA for anticancer activity and prevention of bone metastases. Bisphosphonates, particularly ZA, are generally well tolerated and may likely offer an adjunct therapeutic option for patients with NSCLC.",
keywords = "Bisphosphonates, Bone metastases",
author = "Reshma Mahtani and Raza Khan and Mohammad Jahanzeb",
year = "2011",
month = "1",
day = "1",
doi = "10.3816/CLC.2011.n.003",
language = "English",
volume = "12",
pages = "26--32",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer

AU - Mahtani, Reshma

AU - Khan, Raza

AU - Jahanzeb, Mohammad

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Non-small-cell lung cancer (NSCLC) is frequently characterized by metastases to bone. Bisphosphonates have demonstrated efficacy in reducing the risk of skeletal-related events in cancer patients with bone metastases, including those with NSCLC. Zoledronic acid (ZA) is one of the most potent bisphosphonates and is approved for the first-line treatment of patients with multiple myeloma and bone metastases from solid tumors. Recent preclinical and clinical data suggest that ZA may also have direct and indirect anticancer effects. Several preclinical studies have provided insight into the potential mechanisms responsible for the anticancer activity of ZA, including inhibiting farnesyl pyrophosphate or geranylgeranyl pyrophosphate and activation of immune-mediated anticancer response by γδ T cells. In patients with NSCLC, ZA has been shown to reduce vascular endothelial growth factor levels with a direct correlation to clinical response. Clinical studies in this setting have shown that ZA may also provide a survival benefit and prolong time to progression. Ongoing studies are evaluating the efficacy of ZA for anticancer activity and prevention of bone metastases. Bisphosphonates, particularly ZA, are generally well tolerated and may likely offer an adjunct therapeutic option for patients with NSCLC.

AB - Non-small-cell lung cancer (NSCLC) is frequently characterized by metastases to bone. Bisphosphonates have demonstrated efficacy in reducing the risk of skeletal-related events in cancer patients with bone metastases, including those with NSCLC. Zoledronic acid (ZA) is one of the most potent bisphosphonates and is approved for the first-line treatment of patients with multiple myeloma and bone metastases from solid tumors. Recent preclinical and clinical data suggest that ZA may also have direct and indirect anticancer effects. Several preclinical studies have provided insight into the potential mechanisms responsible for the anticancer activity of ZA, including inhibiting farnesyl pyrophosphate or geranylgeranyl pyrophosphate and activation of immune-mediated anticancer response by γδ T cells. In patients with NSCLC, ZA has been shown to reduce vascular endothelial growth factor levels with a direct correlation to clinical response. Clinical studies in this setting have shown that ZA may also provide a survival benefit and prolong time to progression. Ongoing studies are evaluating the efficacy of ZA for anticancer activity and prevention of bone metastases. Bisphosphonates, particularly ZA, are generally well tolerated and may likely offer an adjunct therapeutic option for patients with NSCLC.

KW - Bisphosphonates

KW - Bone metastases

UR - http://www.scopus.com/inward/record.url?scp=79551533439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551533439&partnerID=8YFLogxK

U2 - 10.3816/CLC.2011.n.003

DO - 10.3816/CLC.2011.n.003

M3 - Article

C2 - 21273176

AN - SCOPUS:79551533439

VL - 12

SP - 26

EP - 32

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -